Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 11/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 11/20 | 0.54 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17781899 | 0.87 | DPP4 (0.47) | DPP4GRIN1GRIN2BNOX4ALDH1A1 | |
| SCHEMBL13591663 | 0.84 | DPP4 (0.56) | DPP4GRIN1GRIN2BNOX4ALDH1A1 | |
| SCHEMBL13142036 | 0.83 | DPP4 (0.46) | DPP4GRIN1GRIN2BCYP3A4 | |
| SCHEMBL14830541 | 0.82 | GRIN1 (0.55) | DPP4GRIN1GRIN2BNOX4KMT2A | |
| SCHEMBL2773928 | 0.82 | PPARG (0.49) | DPP4GRIN1GRIN2BALDH1A1CYP3A4 | |
| SCHEMBL16845974 | 0.82 | DPP4 (0.53) | DPP4GRIN1GRIN2BNOX4KMT2A | |
| SCHEMBL8219650 | 0.79 | DPP4 (0.53) | DPP4ALDH1A1CYP3A4HPGDKMT2A | |
| SCHEMBL8217795 | 0.79 | ALDH1A1 (0.47) | DPP4ALDH1A1CYP3A4HPGDKMT2A | |
| SCHEMBL16845921 | 0.78 | DPP4 (0.51) | DPP4GRIN1GRIN2BNOX4OPRM1 | |
| SCHEMBL8217921 | 0.78 | DPP4 (0.54) | DPP4GRIN1GRIN2BNOX4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112341432-A | Synthesis process of alogliptin benzoate | 重庆化工职业学院 | 2021-02-09 | — | — | CN | claimed |
| CN-111110684-A | Compositions containing a mixture of pyrimidinedione derivatives and uses thereof | 黄泳华 | 2020-05-08 | — | — | CN | claimed |
| US-8188275-B2 | hydrolase enzyme inhibors such as 2-(6-Chloro-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl)-benzonitrile | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-29 | — | — | US | claimed |
| US-20080108808-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | FENG JUN | 2008-05-08 | — | — | US | claimed |
| CN-1926128-A | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO INC (JP) | 2007-03-07 | — | — | CN | claimed |
| US-20050261271-A1 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. | 2005-11-24 | — | — | US | claimed |
| EP-1586571-A1 | Dipeptidyl peptidase inhibitors | Takeda San Diego, Inc. (US) | 2005-10-19 | — | — | EP | claimed |
| WO-2005095381-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-13 | — | — | WO | claimed |
| EP-1931350-B2 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-08-04 | — | — | EP | disclosed |
| CN-112341432-A | Synthesis process of alogliptin benzoate | 重庆化工职业学院 | 2021-02-09 | — | — | CN | disclosed |
| CN-112341432-A | Synthesis process of alogliptin benzoate | 重庆化工职业学院 | 2021-02-09 | — | — | CN | disclosed |
| CN-102079743-B | Dipeptidyl peptidase inhibitors | 武田药品工业株式会社 | 2020-08-25 | — | — | CN | disclosed |
| CN-102134231-B | Dipeptidyl peptidase inhibitors | 武田药品工业株式会社 | 2020-08-04 | — | — | CN | disclosed |
| CN-102134229-B | Dipeptidyl peptidase inhibitors | 武田药品工业株式会社 | 2020-08-04 | — | — | CN | disclosed |
| WO-2007033266-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETIS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-22 | — | — | WO | disclosed |
| CN-1926128-A | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO INC (JP) | 2007-03-07 | — | — | CN | disclosed |
| US-20050261271-A1 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. | 2005-11-24 | — | — | US | disclosed |
| EP-1586571-A1 | Dipeptidyl peptidase inhibitors | Takeda San Diego, Inc. (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2005095381-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095381-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261271-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP9 | DPP4 1/4885GRIN1 3287/4885GRIN2B 3075/4885 |
| US-20080108808-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP3, DPP9 | DPP4 1/4885GRIN1 3287/4885GRIN2B 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.